Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 intratumoral oncolytic virus for unresectable pancreatic cancer
jRCT2073200004Phase 2Suspended
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Apr 2020
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in pancreatic adenocarcinoma (PDAC), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Adverse events and Response rate. Started Apr 2020; status: suspended.
02
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2073200004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2073200004.